For TB-500, "TB-500" returns the synthetic-fragment literature
While recent incretin-based therapies have provided pharmaceutical inroads into treatment of obesity, there remains an ongoing need for additional medicines with distinct modes of action as independent or complementary therapeutics
It is FDA-approved and shown to be a more effective option for some people than single-receptor GLP-1 medications like Semaglutide
DM us or book your appointment today
Suitable for controlled storage and handling in research environments
The method of any one of embodiments 127-135, wherein the composition comprises between about 0.01% to about 10% by weight of the silicon dioxide, about 0.01% to about 7% by weight of the silicon dioxide, about 0.01% to about 5% by weight of the silicon dioxide, about 0.01% to about 3% by weight of the silicon dioxide, about 0.01% to about 2% by weight of the silicon dioxide, or about 0.01% to about 1% by weight of the silicon dioxide
